| 存储条件 |
|---|
| Product Name | HLA-DR [10-D8] |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | DR alpha chain antibody DR alpha chain precursor antibody DRA_HUMAN antibody DRB1 antibody DRB4 antibody Histocompatibility antigen HLA DR alpha antibody HLA class II histocompatibility antigen antibody HLA class II histocompatibility antigen DR alpha chain antibody HLA DR1B antibody HLA DR3B antibody HLA DRA antibody HLA DRA1 antibody HLA DRB1 antibody HLA DRB3 antibody HLA DRB4 antibody HLA DRB5 antibody HLA-DRA antibody HLADR4B antibody HLADRA1 antibody HLADRB antibody Major histocompatibility complex class II DR alpha antibody Major histocompatibility complex class II DR beta 1 antibody Major histocompatibility complex class II DR beta 3 antibody Major histocompatibility complex class II DR beta 4 antibody Major histocompatibility complex class II DR beta 5 antibody MGC117330 antibody MHC cell surface glycoprotein antibody MHC class II antigen DRA antibody MHC II antibody MLRW antibody |
| Product description | Major histocompatibility complex (MHC) class II molecules destined for presentation to CD4+ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in mhc ii-a/b dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane anchored heavy chain and a light chain (β-2-Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles. |
| Immunogen | Peptide |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Host Species | Mouse |
| Tested Applications | WBIHCFC |
| WB:1:250~1:1000 IHC:1:20~1:100 FC:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. | |
| Species Reactivity | Human |
| Concentration | 2mg/ml |
| Alternative Names | DR alpha chain antibody DR alpha chain precursor antibody DRA_HUMAN antibody DRB1 antibody DRB4 antibody Histocompatibility antigen HLA DR alpha antibody HLA class II histocompatibility antigen antibody HLA class II histocompatibility antigen DR alpha chain antibody HLA DR1B antibody HLA DR3B antibody HLA DRA antibody HLA DRA1 antibody HLA DRB1 antibody HLA DRB3 antibody HLA DRB4 antibody HLA DRB5 antibody HLA-DRA antibody HLADR4B antibody HLADRA1 antibody HLADRB antibody Major histocompatibility complex class II DR alpha antibody Major histocompatibility complex class II DR beta 1 antibody Major histocompatibility complex class II DR beta 3 antibody Major histocompatibility complex class II DR beta 4 antibody Major histocompatibility complex class II DR beta 5 antibody MGC117330 antibody MHC cell surface glycoprotein antibody MHC class II antigen DRA antibody MHC II antibody MLRW antibody |
|---|---|
| Molecular Weight(MW) | 29 kDa |
| Cellular Localization | Cell membrane. Endoplasmic reticulum membrane. |
| SwissProt ID | P01903 |
|---|
Application
Fig1: Western blot analysis of HLA-DR on Raji cell lysate using anti-HLA-DR antibody at 1/1,000 dilution.
Application
Fig2: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.
Application
Fig3: Immunohistochemical analysis of paraffin-embedded human lung cancer tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.
Application
Fig4: Immunohistochemical analysis of paraffin-embedded human colon cancer tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.
Application
Fig5: Immunohistochemical analysis of paraffin-embedded human skin tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.
Application
Fig6: Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-HLA-DR antibody. Counter stained with hematoxylin.
Application
Fig7: Flow cytometric analysis of Daudi cells with HLA-DR antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).| Positive Control | Raji, human tonsil tissue, human lung cancer tissue, human colon cancer tissue, human kidney tissue, human skin tissue, Daudi. |
|---|---|
| Application Notes | WB:1:250~1:1000 IHC:1:20~1:100 FC:1:100~1:200 Notes:Optimal dilutions/concentrations should be determined by the researcher. |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 0.5%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide. |
抱歉，暂无相关文献
